Palonosetron Injection Suppliers & Bulk Manufacturers
Available Forms: IV Injection
Available Strengths: 0.25 mg/5 mL (0.05 mg/mL)
Reference Brands: Aloxi (US & EU)
Category:
Oncology Cancer Care
Palonosetron Injection is a long-acting antiemetic used to prevent CINV and PONV, available as 0.25 mg/5 mL and 0.075 mg/mL IV doses. Marketed under Aloxi® in the US and EU, it offers extended protection and is ideal for oncology settings. GMP-compliant and available in both branded and generic forms, Palonosetron is a reliable choice for pharma partners across Europe and North America.
Palonosetron Injection is available in IV Injection
and strengths such as 0.25 mg/5 mL (0.05 mg/mL).
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Palonosetron Injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Palonosetron Injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Palonosetron Injection is a next-generation 5-HT3 receptor antagonist used to prevent chemotherapy-induced and post-operative nausea and vomiting (CINV & PONV). Known for its long half-life and superior efficacy, Palonosetron provides extended protection against both acute and delayed emesis. It is available in 0.25 mg/5 mL and 0.075 mg/mL IV formulations, ideal for hospital and oncology settings. Marketed under Aloxi® in the US and EU, and also offered in generic form, it is manufactured under GMP-certified conditions. Palonosetron is a preferred antiemetic for pharmaceutical distributors seeking reliable oncology support across Europe and North America.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing